More: Medscape Perspectives on the American Psychiatric Association (APA) 161st Annual Meeting

APA 2008: Advances in Schizophrenia: New Findings in Detection and Prevention, Treatment, and Pharmacogenetics CME

May 3 - 8, 2008, Washington, DC

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the American Psychiatric Association. Conference news does not receive grant support and is produced independently.

Release Date: June 26, 2008; Valid for credit through June 26, 2009

Credits Available
Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Psychiatric Association. These materials and the related activity are not sanctioned by the American Psychiatric Association or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Medscape
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Describe the latest findings regarding advances in the detection and prevention of schizophrenia
  2. Discuss novel approaches to treating schizophrenia
  3. Review advances in pharmacogenetics of serious mental illness
Authors and Disclosures

Michael T. Compton, MD, MPH
Disclosure: Michael T. Compton, MD, MPH, has disclosed that he has received grants for clinical research from AstraZeneca, National Institute of Mental Health, and the American Psychiatric Association, as well as grants for educational activities from Janssen. Dr. Compton has also disclosed that he has been a consultant for AstraZeneca.


Bret Stetka, MD
Disclosure: Bret Stetka, MD, has disclosed no relevant financial relationships.


 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.